Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 3369 | 1924 | 26.7 | 78% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | CA 125 | Author keyword | 324 | 43% | 30% | 581 |
| 2 | HE4 | Author keyword | 255 | 89% | 6% | 115 |
| 3 | HUMAN EPIDIDYMIS PROTEIN 4 | Author keyword | 98 | 100% | 2% | 29 |
| 4 | WFDC2 | Author keyword | 18 | 89% | 0% | 8 |
| 5 | RISK OF OVARIAN MALIGNANCY ALGORITHM | Author keyword | 15 | 88% | 0% | 7 |
| 6 | CA 125 ANTIGEN | Author keyword | 14 | 41% | 1% | 27 |
| 7 | MUC16 | Author keyword | 13 | 44% | 1% | 22 |
| 8 | HUMAN EPIDIDYMIS PROTEIN 4 HE4 | Author keyword | 11 | 78% | 0% | 7 |
| 9 | CNR IBPM | Address | 8 | 75% | 0% | 6 |
| 10 | CARBOHYDRATE ANTIGEN 125 | Author keyword | 8 | 40% | 1% | 16 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | CA 125 | 324 | 43% | 30% | 581 | Search CA+125 | Search CA+125 |
| 2 | HE4 | 255 | 89% | 6% | 115 | Search HE4 | Search HE4 |
| 3 | HUMAN EPIDIDYMIS PROTEIN 4 | 98 | 100% | 2% | 29 | Search HUMAN+EPIDIDYMIS+PROTEIN+4 | Search HUMAN+EPIDIDYMIS+PROTEIN+4 |
| 4 | WFDC2 | 18 | 89% | 0% | 8 | Search WFDC2 | Search WFDC2 |
| 5 | RISK OF OVARIAN MALIGNANCY ALGORITHM | 15 | 88% | 0% | 7 | Search RISK+OF+OVARIAN+MALIGNANCY+ALGORITHM | Search RISK+OF+OVARIAN+MALIGNANCY+ALGORITHM |
| 6 | CA 125 ANTIGEN | 14 | 41% | 1% | 27 | Search CA+125+ANTIGEN | Search CA+125+ANTIGEN |
| 7 | MUC16 | 13 | 44% | 1% | 22 | Search MUC16 | Search MUC16 |
| 8 | HUMAN EPIDIDYMIS PROTEIN 4 HE4 | 11 | 78% | 0% | 7 | Search HUMAN+EPIDIDYMIS+PROTEIN+4+HE4 | Search HUMAN+EPIDIDYMIS+PROTEIN+4+HE4 |
| 9 | CARBOHYDRATE ANTIGEN 125 | 8 | 40% | 1% | 16 | Search CARBOHYDRATE+ANTIGEN+125 | Search CARBOHYDRATE+ANTIGEN+125 |
| 10 | SERUM CA 125 | 8 | 45% | 1% | 13 | Search SERUM+CA+125 | Search SERUM+CA+125 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CA 125 | 331 | 41% | 32% | 625 |
| 2 | PELVIC MASS | 140 | 72% | 6% | 110 |
| 3 | SERUM CA 125 LEVELS | 94 | 50% | 7% | 137 |
| 4 | CA 125 LEVELS | 87 | 54% | 6% | 113 |
| 5 | EPIDIDYMIS PROTEIN 4 | 76 | 88% | 2% | 36 |
| 6 | BIOMARKER PANELS | 65 | 95% | 1% | 21 |
| 7 | CA 125 ANTIGEN | 50 | 86% | 1% | 25 |
| 8 | TUMOR MARKER CA 125 | 41 | 100% | 1% | 15 |
| 9 | SERUM CA 125 | 38 | 34% | 5% | 94 |
| 10 | MALIGNANCY ALGORITHM | 36 | 79% | 1% | 23 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Role of tumour markers in monitoring epithelial ovarian cancer | 2000 | 150 | 32 | 78% |
| Detection and monitoring of ovarian cancer | 2013 | 25 | 48 | 58% |
| Ovarian cancer screening-Current status, future directions | 2014 | 12 | 49 | 39% |
| Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer | 2014 | 16 | 38 | 26% |
| Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review | 2013 | 16 | 28 | 68% |
| MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress | 2014 | 7 | 160 | 48% |
| Diagnostic Value of Serum Human Epididymis Protein 4 (HE4) in Ovarian Carcinoma A Systematic Review and Meta-Analysis | 2012 | 13 | 17 | 88% |
| The Role of HE4 in Ovarian Cancer Follow-up A Review | 2014 | 3 | 16 | 81% |
| TUMOR-MARKERS IN THE MANAGEMENT OF PATIENTS WITH OVARIAN-CANCER | 1995 | 85 | 125 | 74% |
| Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis | 2013 | 9 | 29 | 76% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CNR IBPM | 8 | 75% | 0.3% | 6 |
| 2 | IMMUNOCHEM GLYCOBIOL | 5 | 63% | 0.3% | 5 |
| 3 | BIOMARKERS EMERGING TECHNOL | 3 | 100% | 0.2% | 3 |
| 4 | TRANSLAT OUTCOMES | 2 | 67% | 0.1% | 2 |
| 5 | BRANCH UTERINE CANC | 1 | 38% | 0.2% | 3 |
| 6 | PROGRAM WOMENS ONCOL OBSTET GYNECOL | 1 | 50% | 0.1% | 2 |
| 7 | ZIMMER CANC | 1 | 100% | 0.1% | 2 |
| 8 | HOSP SALUD ZENON SANTILLAN | 1 | 40% | 0.1% | 2 |
| 9 | GYNECOL SURG GYNECOL ONCOL ADULTS ADOLES | 1 | 25% | 0.2% | 3 |
| 10 | TUMOR MARKERS | 1 | 19% | 0.2% | 4 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000142843 | RISK OF MALIGNANCY INDEX//ADNEXAL MASSES//ADNEXAL MASS |
| 2 | 0.0000118223 | TETRANECTIN//CLIN BICHEM//SERONEGATIVE SPONDYLARTHRITIS |
| 3 | 0.0000111559 | SQUAMOUS CELL CARCINOMA ANTIGEN//SCC ANTIGEN//SERPINB3 |
| 4 | 0.0000109929 | CA 15 3//CA 153//TISSUE POLYPEPTIDE SPECIFIC ANTIGEN |
| 5 | 0.0000098117 | CA 19 9//CA19 9//SPAN 1 |
| 6 | 0.0000080404 | INTERVAL DEBULKING SURGERY//SECONDARY CYTOREDUCTIVE SURGERY//ADVANCED OVARIAN CANCER |
| 7 | 0.0000080224 | MASSIVE OVARIAN EDEMA//MEIGS SYNDROME//PSEUDO MEIGS SYNDROME |
| 8 | 0.0000058477 | CYFRA 21 1//CYTOKERATIN 19 FRAGMENTS//PROGRP |
| 9 | 0.0000054489 | TUMOR ASSOCIATED TRYPSIN INHIBITOR//TATI//PEC 60 |
| 10 | 0.0000053238 | PLATINUM RESISTANT//RECURRENT OVARIAN CANCER//PEGYLATED LIPOSOMAL DOXORUBICIN |